S Arjani1, T J Bostonian1, V Prasath1, P L Quinn2, R J Chokshi3. 1. Rutgers New Jersey Medical School, Newark, NJ, USA. 2. Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA. 3. Department of Surgery, Division of Surgical Oncology, Rutgers New Jersey Medical School, 205 South Orange Ave, F1222, Newark, NJ, 07103, USA. chokshrj@njms.rutgers.edu.
Abstract
PURPOSE: Adrenalectomies performed for the treatment of primary aldosteronism due to unilateral adenoma are traditionally confirmed with, and guided by, results from adrenal vein sampling (AVS). However, the usefulness of AVS at the expense of cost and complications is debated, and many institutions have independent protocols that use AVS to varying degrees. METHODS: Cost-effectiveness of AVS- vs computed tomography (CT)-based adrenalectomy was calculated using decision tree models. The tree was populated with values describing biochemical post-operative outcomes from the published literature; patients were placed into AVS- or CT-dependent treatment arms. Biochemical outcomes were defined based on patients' potassium levels and aldosterone-renin ratios. Patients underwent adrenalectomies and received medical management dosed based on surgical outcomes. Costs were represented by Medicare (FY2021) reimbursement rates (US$) and quality-adjusted life-years (QALYs) were calculated using published morbidity and survival data. A willingness-to-pay of $100,000 per QALY gained was set to determine the most cost-effective strategy. The primary outcome was the incremental cost-effectiveness ratio (ICER) associated with biochemical outcomes. RESULTS: The base case analyses favored the use of AVS-guided care, which cost $307.65 more but yielded 0.78 more QALYs, resulting in an ICER of $392.57. These results were upheld by all one-way and two-way sensitivity analyses. In 100,000 random-sampling simulations, AVS-guided care was favored 100% of the time. CONCLUSIONS: For patients with primary aldosteronism receiving adrenalectomies with curative intent, the more cost-effective method based on biochemical outcomes is AVS-based care. Recent literature suggests biochemical resolution should be favored over clinical resolution, due to long-term detriments of increased aldosterone independent of clinical symptoms.
PURPOSE: Adrenalectomies performed for the treatment of primary aldosteronism due to unilateral adenoma are traditionally confirmed with, and guided by, results from adrenal vein sampling (AVS). However, the usefulness of AVS at the expense of cost and complications is debated, and many institutions have independent protocols that use AVS to varying degrees. METHODS: Cost-effectiveness of AVS- vs computed tomography (CT)-based adrenalectomy was calculated using decision tree models. The tree was populated with values describing biochemical post-operative outcomes from the published literature; patients were placed into AVS- or CT-dependent treatment arms. Biochemical outcomes were defined based on patients' potassium levels and aldosterone-renin ratios. Patients underwent adrenalectomies and received medical management dosed based on surgical outcomes. Costs were represented by Medicare (FY2021) reimbursement rates (US$) and quality-adjusted life-years (QALYs) were calculated using published morbidity and survival data. A willingness-to-pay of $100,000 per QALY gained was set to determine the most cost-effective strategy. The primary outcome was the incremental cost-effectiveness ratio (ICER) associated with biochemical outcomes. RESULTS: The base case analyses favored the use of AVS-guided care, which cost $307.65 more but yielded 0.78 more QALYs, resulting in an ICER of $392.57. These results were upheld by all one-way and two-way sensitivity analyses. In 100,000 random-sampling simulations, AVS-guided care was favored 100% of the time. CONCLUSIONS: For patients with primary aldosteronism receiving adrenalectomies with curative intent, the more cost-effective method based on biochemical outcomes is AVS-based care. Recent literature suggests biochemical resolution should be favored over clinical resolution, due to long-term detriments of increased aldosterone independent of clinical symptoms.
Authors: Tanja Dekkers; Aleksander Prejbisz; Leo J Schultze Kool; Hans J M M Groenewoud; Marieke Velema; Wilko Spiering; Sylwia Kołodziejczyk-Kruk; Mark Arntz; Jacek Kądziela; Johannes F Langenhuijsen; Michiel N Kerstens; Anton H van den Meiracker; Bert-Jan van den Born; Fred C G J Sweep; Ad R M M Hermus; Andrzej Januszewicz; Alike F Ligthart-Naber; Peter Makai; Gert-Jan van der Wilt; Jacques W M Lenders; Jaap Deinum Journal: Lancet Diabetes Endocrinol Date: 2016-06-17 Impact factor: 32.069
Authors: Tracy A Williams; Jacopo Burrello; Leonardo A Sechi; Carlos E Fardella; Joanna Matrozova; Christian Adolf; René Baudrand; Stella Bernardi; Felix Beuschlein; Cristiana Catena; Michalis Doumas; Francesco Fallo; Gilberta Giacchetti; Daniel A Heinrich; Gaëlle Saint-Hilary; Pieter M Jansen; Andrzej Januszewicz; Tomaz Kocjan; Tetsuo Nishikawa; Marcus Quinkler; Fumitoshi Satoh; Hironobu Umakoshi; Jiří Widimský; Stefanie Hahner; Stella Douma; Michael Stowasser; Paolo Mulatero; Martin Reincke Journal: Hypertension Date: 2018-09 Impact factor: 10.190
Authors: John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young Journal: J Clin Endocrinol Metab Date: 2016-03-02 Impact factor: 5.958
Authors: Tracy A Williams; Jacques W M Lenders; Paolo Mulatero; Jacopo Burrello; Marietta Rottenkolber; Christian Adolf; Fumitoshi Satoh; Laurence Amar; Marcus Quinkler; Jaap Deinum; Felix Beuschlein; Kanako K Kitamoto; Uyen Pham; Ryo Morimoto; Hironobu Umakoshi; Aleksander Prejbisz; Tomaz Kocjan; Mitsuhide Naruse; Michael Stowasser; Tetsuo Nishikawa; William F Young; Celso E Gomez-Sanchez; John W Funder; Martin Reincke Journal: Lancet Diabetes Endocrinol Date: 2017-05-30 Impact factor: 32.069